A federal jury in the Middle District of Tennessee has convicted Heather Marks, 43, a nurse practitioner from Murfreesboro, of nine federal counts related to the illegal distribution of controlled substances. The conviction stems from her work at Lifeforce Pain and Wellness clinic in Carthage, Tennessee, where prosecutors say Marks prescribed opioids outside the bounds of legitimate medical practice from 2016 through 2018. According to the Department of Justice, Marks issued prescriptions for approximately one million opioid pills to roughly 1,000 patients over that two-year window — an average of 1,000 pills per patient per year, or nearly 3 pills per patient per day without interruption.
The jury found Marks guilty of one count of conspiracy to distribute and dispense controlled substances and eight counts of illegal distribution of controlled substances. Sentencing is scheduled for September 1, 2026, before U.S. District Court. The charges carry a maximum penalty of 20 years in federal prison per count — a potential life sentence in aggregate.
Federal prosecutors described the Lifeforce clinic as a cash-pay operation where Marks conducted superficial examinations before issuing prescriptions for opioids. Court filings state that she was aware many patients showed signs of active addiction and that some were likely reselling the medications they received. In trial testimony, investigators described patients driving hours to the clinic, paying in cash, receiving prescriptions without meaningful medical justification, and returning on regular cycles for refills. The investigation was a joint effort by the FBI, the Department of Health and Human Services Office of Inspector General, and the Tennessee Bureau of Investigation — a coordination of federal and state law enforcement resources that typically signals a case the government had built over years before bringing charges.
The nurse practitioner scope question no one wants to touch
Tennessee is a collaborative practice state for nurse practitioners — meaning NPs must have a formal written collaborative agreement with a supervising physician to prescribe controlled substances. Court documents do not yet specify the details of Marks's collaborative arrangement at Lifeforce or whether the supervising physician faced any federal scrutiny. But the case raises a question that is uncomfortable for the NP profession and for scope-of-practice advocates: what oversight structures existed between Marks and her collaborating physician, and were they meaningful or nominal?
That question has no easy answer. The opioid crisis has produced prosecutions of both physicians and advanced practice providers who operated pill mills, and the pattern in those cases is consistent: nominal oversight on paper, no meaningful review of prescribing volume or patient outcomes in practice. The collaborative agreement model does not inherently prevent this — it creates a named supervisor, not an enforced supervisory relationship. States that have moved to full practice authority (FPA) for NPs argue that FPA removes the fiction of supervision and replaces it with direct board accountability. States like Tennessee counter that supervised practice provides a check. This case suggests the check, in this instance, was not functioning.
Prescribing one million opioid pills to a thousand patients over two years is not a gray area. That is not an overly aggressive pain management philosophy or a misread of prescribing guidelines. The math alone makes it impossible to argue this was legitimate clinical practice. What this case does — and what cases like it always do — is trigger a reflexive response to restrict NP prescribing authority broadly. That response is wrong, and it punishes the overwhelming majority of NPs who practice responsibly and ethically. What it should prompt instead is a real conversation about collaborative agreement oversight: are physician collaborators actually reviewing prescribing patterns at meaningful intervals, or are they co-signing paperwork for a monthly fee? Because if it's the latter — and in too many cases it is — the "supervision" that scope opponents point to as a safety mechanism is fiction. This case is about fraud, not about nurse practitioners as a class.
For nurses and NPs currently practicing in Tennessee or other collaborative states, the Marks case is a reminder that the standard of care — not just DEA scheduling rules — governs controlled substance prescribing. Prescribing outside the bounds of legitimate medical purpose is a federal criminal offense regardless of whether you hold a DEA registration. The presence of a collaborative agreement does not indemnify a prescriber who is knowingly issuing prescriptions for cash to patients with no legitimate medical need.